Twenty five years after identification of the HIV virus, the AIDS epidemic continues with an estimated 33 million individuals currently infected worldwide and 2.5 million new infections each year. Research to prevent and treat HIV infection has grown increasing sophisticated and the analytic challenges have become correspondingly complex. In this application we outline plans for the development of statistical methods that will be directly applicable to current problems in the field of HIV/AIDS research. In particular, we propose to develop methods for the analysis of data from stepped wedge randomized trials, trials to prevent mother to child transmission of HIV, discordant partner studies, and trials or studies which utilize two-phase or other complex sampling designs. Since HIV infection is typically asymptomatic and the time of infection is bounded by two test dates, we continue work on methods for interval censored data and focus on issues related to competing risks and correlated interval censored data. Finally, as the search for an effective HIV vaccine presents ever greater challenges, we propose to develop novel statistical methods for analyzing data from studies of T-cell based vaccines as well as HIV antigen-antibody interactions.

Public Health Relevance

This research will develop statistical methods for use in studies of HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI029168-23
Application #
8259854
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Gezmu, Misrak
Project Start
1989-09-30
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
23
Fiscal Year
2012
Total Cost
$315,055
Indirect Cost
$86,293
Name
University of Washington
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Mao, Lu; Lin, D Y (2016) Semiparametric regression for the weighted composite endpoint of recurrent and terminal events. Biostatistics 17:390-403
Koepke, Amanda A; Longini Jr, Ira M; Halloran, M Elizabeth et al. (2016) PREDICTIVE MODELING OF CHOLERA OUTBREAKS IN BANGLADESH. Ann Appl Stat 10:575-595
Dai, James Y; Hendrix, Craig W; Richardson, Barbra A et al. (2016) Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. J Infect Dis 213:335-42
Fleming, Thomas R; Ellenberg, Susan S (2016) Evaluating interventions for Ebola: The need for randomized trials. Clin Trials 13:6-9
Norwood, Marlena S; Hughes, James P; Amico, K Rivet (2016) The validity of self-reported behaviors: methods for estimating underreporting of risk behaviors. Ann Epidemiol 26:612-618.e2
Wang, Lianming; McMahan, Christopher S; Hudgens, Michael G et al. (2016) A flexible, computationally efficient method for fitting the proportional hazards model to interval-censored data. Biometrics 72:222-31
Cumberland, William N; Fong, Youyi; Yu, Xuesong et al. (2015) Nonlinear Calibration Model Choice between the Four and Five-Parameter Logistic Models. J Biopharm Stat 25:972-83
Breslow, Norman E; Hu, Jie; Wellner, Jon A (2015) Z-estimation and stratified samples: application to survival models. Lifetime Data Anal 21:493-516
Odem-Davis, K; Fleming, T R (2015) A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect. Stat Biopharm Res 7:12-24
Fleming, Thomas R (2015) Protecting the confidentiality of interim data: addressing current challenges. Clin Trials 12:5-11

Showing the most recent 10 out of 94 publications